GE HealthCare Technologies Inc.
GEHCNext catalyst
Regadenoson
Myocardial Ischemia
Get an email about GEHC's next catalysts
Track GE HealthCare Technologies (GEHC) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
No other upcoming event in our data.
1 upcoming, 1 past
Regadenoson Phase 2 Est. Readout
Primary completion for Regadenoson trial (NCT04604782) in Myocardial Ischemia
SourceMarket Overview
Stock performance and key metrics
GE Healthcare Technologies, Inc., stylized GE HealthCare, is an American health technology company based in Chicago, Illinois. It operates four divisions: Medical imaging, which includes molecular imaging, computed tomography, magnetic resonance, women’s health screening and X-ray systems; Ultrasound; Patient Care Solutions, which is focused on remote patient monitoring, anesthesia and respiratory care, diagnostic cardiology, and infant care; and Pharmaceutical Diagnostics, which manufactures contrast agents and radiopharmaceuticals.
WebsiteDatSCAN
Lewy Body Dementia
DaTSCAN™ Ioflupane (123I) Injection
Parkinsonian Syndrome
SPECT
Parkinson Disease
Sonazoid™
Liver Lesions
123I-mIBG (meta-iodobenzylguanidine)
Heart Failure, Congestive
Gadodiamide Injection
Aorto-iliac Stenosis
[18F] Flutemetamol
Normal Pressure Hydrocephalus
Flutemetamol (18F) Injection
Mild Cognitive Impairment
[18F]Flutemetamol
Alzheimer's Disease
PET MPI
Coronary Artery Disease (CAD)
GE-145 (AN113111) Injection
Healthy
GE-145
Chronic Renal Insufficiency
Regadenoson
Myocardial Ischemia
Ioforminol 160 mgI/mL
Healthy
Flurpiridaz (18F) Injection
Coronary Artery Disease (CAD)
Fluciclatide Injection
Solid Tumors
Fluciclatide Injection - (AH111585 (F18))
High-grade Glioma
AH110690 (18F) Injection
Alzheimer's Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
DatSCAN | Phase 3 | Lewy Body Dementia | - | - |
DaTSCAN™ Ioflupane (123I) Injection | Phase 3 | Parkinsonian Syndrome | - | - |
SPECT | Phase 3 | Parkinson Disease | - | - |
Sonazoid™ | Phase 3 | Liver Lesions | - | - |
123I-mIBG (meta-iodobenzylguanidine) | Phase 3 | Heart Failure, Congestive | - | - |
Gadodiamide Injection | Phase 3 | Aorto-iliac Stenosis | - | - |
[18F] Flutemetamol | Phase 3 | Normal Pressure Hydrocephalus | - | - |
Flutemetamol (18F) Injection | Phase 3 | Mild Cognitive Impairment | - | - |
[18F]Flutemetamol | Phase 3 | Alzheimer's Disease | - | - |
PET MPI | Phase 3 | Coronary Artery Disease (CAD) | - | - |
GE-145 (AN113111) Injection | Phase 2 | Healthy | - | - |
GE-145 | Phase 2 | Chronic Renal Insufficiency | - | - |
Regadenoson | Phase 2 | Myocardial Ischemia | - | - |
Ioforminol 160 mgI/mL | Phase 2 | Healthy | - | - |
Flurpiridaz (18F) Injection | Phase 2 | Coronary Artery Disease (CAD) | - | - |
Fluciclatide Injection | Phase 2 | Solid Tumors | - | - |
Fluciclatide Injection - (AH111585 (F18)) | Phase 2 | High-grade Glioma | - | - |
AH110690 (18F) Injection | Phase 2 | Alzheimer's Disease | - | - |
Frequently asked questions
What is in GE HealthCare Technologies Inc.'s drug pipeline?→
CatalystAlert tracks 18 drug candidates in GE HealthCare Technologies Inc.'s (GEHC) pipeline across Phase 3, Phase 2. Its lead program is [18F] Flutemetamol (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is GE HealthCare Technologies Inc.'s next FDA catalyst?→
GE HealthCare Technologies Inc.'s (GEHC) next tracked catalyst is a Phase 2 readout expected December 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track GEHC biotech catalysts?→
Add GEHC to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow GE HealthCare Technologies Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.